Irinotecan hydrochloride is under clinical development by Edison Oncology Holding and currently in Phase II for Rhabdomyosarcoma. According to GlobalData, Phase II drugs for Rhabdomyosarcoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Irinotecan hydrochloride LoA Report. Buy the report here.
Recommended Buyer's Guides
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Irinotecan hydrochloride overview
irinotecan hydrochloride is under development for the treatment of recurrent pediatric solid tumors including neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma. The drug candidate is administered by oral route as solution. It is a small molecule and acts by targeting topoisomerase I.
Edison Oncology Holding overview
Edison Oncology Holding is a biopharmaceutical company engaged in the development and commercialization of new therapies targeting the fight against cancer. The company is headquartered in Menlo Park, California, the US.
For a complete picture of Irinotecan hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
